Licence variation: spironolactone for acne in women
NHS England · Awarded
- Buyer
- NHS England
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Professional Services
- Reference
- FaT-ocds-h6vhtk-045808
- Published
- 2025-01-17
- Deadline
- 2026-04-18
Tender summary
NHS England required a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data.
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access